A retrospective study comparing the clinical efficacy of 2.5g and 5g doses of Idarucizumab used in Dabigatran reversal in three hospitals in Auckland
Latest Information Update: 30 Nov 2021
At a glance
- Drugs Idarucizumab (Primary)
- Indications Blood coagulation disorders
- Focus Therapeutic Use
- 30 Nov 2021 New trial record
- 23 Nov 2021 Results published in the Thrombosis and Haemostasis